Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

novel antiplatelet agent that can potentially prevent the formation of deadly blood clots without adding a significant bleeding risk (in Phase III); approximately 13,000 patients have been enrolled in its Phase III program targeted to include 30,000 patients;
  • SIMPONI(TM)* (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets;
  • SAPHRIS(TM)** (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder); pivotal relapse-prevention data were presented showing that only 12 percent of patients receiving asenapine relapsed at the specified endpoint versus 47 percent of patients receiving placebo;
  • BRIDION(R) (sugammadex), the first and only selective relaxant binding agent for reversing neuromuscular blockade in anesthesia (approved in EU; under review in U.S. and Japan);
  • Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ribavirin combination therapy (in Phase III); 24-week sustained viral response (SVR) data were presented showing that 75 percent of patients achieved SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was unveiled, with the potential to offer once-daily dosing and having 10 times the in vitro potency of current protease inhibitors in late-phase development;
  • Mometasone furoate and formoterol (MFF), an inhaled combination therapy for asthma and COPD (completing Phase III); pivotal data from Phase III trials in asthma were presented showing that MFF met its primary endpoints; and
  • Preladenant, a nov
    '/>"/>

    • SOURCE Schering-Plough Corporation
    Copyright©2008 PR Newswire.
    All rights reserved

    5

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
    2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
    3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
    4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
    5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
    6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
    7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
    8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
    11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
    (Date:12/16/2009)... Naurex Inc., a new clinical stage ... CNS disorders based on its novel GFPA NMDA ... a Phase I clinical trial of its lead ... subjects in the study. GLYX-13, a glycine ... the NMDA receptor, is initially being developed as ...
    (Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
    Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 1Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 2Pesticide Residue Common on Kitchen Floors 49522 1Pesticide Residue Common on Kitchen Floors 49522 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 1Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 4
    (Date:12/16/2009)... pinpoint seven that increase susceptibility to disease , , ... associated with increased susceptibility to leprosy have been ... The researchers, who analyzed more than 10,000 DNA ... China, said their discovery highlights the important role ... development of leprosy. , "Though leprosy is not ...
    (Date:12/16/2009)... The omega-3 essential fatty acids commonly found ... sensory overload, according to research published by the ... to the information-processing problems found in people with ... disease; and other afflictions of the nervous system. ... Behavioral Neuroscience , provides more evidence that ...
    (Date:12/16/2009)... global leader of Digital Pen and Paper technology and the ... trials, today announced that it is ranked among the Fastest ... EMEA 2009. , ... (PRWEB) December ... solutions for the capture, digitalization and management of handwritten data. ...
    (Date:12/16/2009)... all-time low, government report shows, , , WEDNESDAY, Dec. 16 ... States has reached almost 78 years, a record high, ... 2007, women can expect to live to 80.4 years ... the report from the U.S. Centers for Disease Control ... expect to live longer than their parents, life expectancy ...
    (Date:12/16/2009)... New research published online, December ... pistachios, and molecules present in pistachios, have ... levels of an inflammatory marker known as ... Inflammation is a complex biological response to ... and it underlies functional changes associated with ...
    Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
    ... June 5 Soaring gas prices are,a contributing factor ... on,the poorest and most vulnerable within the global community ... situation is particularly devastating in Ethiopia, one of the ... in 2007 and again in 2008,compounded the Ethiopian situation, ...
    ... ) today reported preliminary total retail drug,store sales for the four-week and seventeen-week periods ended May 29,2008., ... Periods ended May 29, 2008 ... Month Year to Date (Dollars ... (4 weeks) (17 weeks), Total retail drug store sales ...
    ... A Closer Look at The Value of,MRIs ... of,America,s (MSAA) website, http://www.msassociation.org . This three ... offering a first-hand,account on the experience of undergoing ... well as the importance of MRIs to monitor ...
    ... Benchmarking is not a luxury;,it is an activity that ... a survey analysis of 30 companies and in-depth interviews,with ... benchmarking in a,difficult economy., The complete study addresses ... the goals of benchmarking studies, how companies are,demonstrating value ...
    ... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
    ... entertainment and ... more, ... fitness and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at ... Centre in Atlanta., Chad, part of the World Natural Bodybuilding Federation ...
    Other Medicine News:Health News:Impact of Rising Gas, Food Prices Felt Globally 2Health News:Longs Reports Preliminary May Retail Drug Store Sales 2Health News:Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs 2Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: